The interaction between St John's wort and an oral contraceptive

Objectives: The popular herbal remedy St John’s wort is an inducer of cytochrome P450 (CYP) 3A enzymes and may reduce the efficacy of oral contraceptives. Therefore we evaluated the effect of St John’s wort on the disposition and efficacy of Ortho-Novum 1/35 (Ortho-McNeil Pharmaceutical, Inc, Raritan, NJ), a popular combination oral contraceptive pill containing ethinyl estradiol (INN, ethinylestradiol) and norethindrone (INN, norethisterone). Methods: Twelve healthy premenopausal women who were using oral contraception (>3 months) received a combination oral contraceptive pill (Ortho-Novum 1/35) for 3 consecutive 28-day menstrual cycles. During the second and third cycles, the participants received 300 mg St John’s wort 3 times a day. The serum concentrations of ethinyl estradiol (day 7), norethindrone (day 7), follicle-stimulating hormone (days 1216), luteinizing hormone (days 12-16), progesterone (day 21), and intravenous and oral midazolam (days 22 and 23) were determined in serial blood samples. The incidence of breakthrough bleeding was quantified during the first and third cycles. Results: Concomitant use of St John’s wort was associated with a significant (P .05). Breakthrough bleeding occurred in 2 of 12 women in the control phase compared with 7 of 12 women in the St John’s wort phase. The oral clearance of midazolam after St John’s wort dosing was greater in women who had breakthrough bleeding (215.9 66.5 L/h) than in those who did not (97.5 37.2 L/h) (P .005). Conclusion: St John’s wort causes an induction of ethinyl estradiol–norethindrone metabolism consistent with increased CYP3A activity. Women taking oral contraceptive pills should be counseled to expect breakthrough bleeding and should consider adding a barrier method of contraception when consuming St Johns wort. (Clin Pharmacol Ther 2003;74:525-35.)